Coronavirus: Vaccination

(asked on 9th February 2021) - View Source

Question to the Department for Business, Energy and Industrial Strategy:

To ask Her Majesty's Government which projects are funded by UK Research and Innovation to support research on vaccine responses in groups of immune-supressed individuals; and, in each case, what is (1) the level of funding, and (2) the project timetable.


Answered by
Lord Callanan Portrait
Lord Callanan
Parliamentary Under Secretary of State (Department for Energy Security and Net Zero)
This question was answered on 23rd February 2021

UKRI is currently funding one study of direct relevance to these areas. UKRI has allocated an initial £1.8 million to the OCTAVE study, led by Professor Iain McInnes, University of Glasgow, for a twelve-month period, and is considering a case for additional funding beyond this. OCTAVE is supporting research on vaccine responses in groups of immune-supressed individuals, including those with inflammatory disorders, high risk cancer patient groups, and patients with severe kidney and liver disease. Cancer patient groups include chronic lymphocytic leukaemia, myeloma, acute leukaemia, and bone marrow transplants. As the OCTAVE study is being managed as a single project it is not possible to give costs for the individual groups.

In addition, there are proposals on vaccine responses in high-risk clinical groups under consideration as part of the UKRI COVID-19 Agile call, with announcements to be made shortly. Furthermore, UKRI continues to accept applications for COVID-19 related research, including on this topic, through its active calls, which can be found on the UKRI website.

Reticulating Splines